LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 164

Search options

  1. Book ; Conference proceedings: Biological markers in dementia of Alzheimer type

    Fowler, Christopher J.

    proceedings of the Stiftelsen Gamla Tjänarinnor Symposium on Aging and Aging Disorders no. 1, [held in Stockholm, 24 - 25 August 1989]

    (Aging and aging disorders ; 1)

    1990  

    Institution Stiftelsen Gamla Tjänarinnor
    Event/congress Symposium on Aging and Aging Disorders (1, 1989, Stockholm)
    Author's details ed. by Christopher J. Fowler
    Series title Aging and aging disorders ; 1
    Collection
    Keywords Alzheimer Disease / congresses ; Biological Markers / congresses
    Size VIII, 232 S. : Ill., graph. Darst.
    Publisher Smith-Gordon u.a.
    Publishing place London
    Publishing country Great Britain
    Document type Book ; Conference proceedings
    HBZ-ID HT003603673
    ISBN 1-85463-031-8 ; 978-1-85463-031-5
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  2. Article ; Online: The Basal Pharmacology of Palmitoylethanolamide.

    Rankin, Linda / Fowler, Christopher J

    International journal of molecular sciences

    2020  Volume 21, Issue 21

    Abstract: Palmitoylethanolamide (PEA, ...

    Abstract Palmitoylethanolamide (PEA,
    MeSH term(s) Amides/pharmacokinetics ; Amides/pharmacology ; Analgesics/chemistry ; Analgesics/pharmacology ; Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; Biological Availability ; Ethanolamines/pharmacokinetics ; Ethanolamines/pharmacology ; Gene Expression Regulation/drug effects ; Humans ; PPAR alpha/metabolism ; Palmitic Acids/pharmacokinetics ; Palmitic Acids/pharmacology ; Receptors, Cannabinoid/metabolism ; Tissue Distribution
    Chemical Substances Amides ; Analgesics ; Anti-Inflammatory Agents, Non-Steroidal ; Ethanolamines ; GPR55 protein, human ; PPAR alpha ; PPARA protein, human ; Palmitic Acids ; Receptors, Cannabinoid ; palmidrol (6R8T1UDM3V)
    Language English
    Publishing date 2020-10-26
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms21217942
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.

    Fowler, Christopher J

    Handbook of experimental pharmacology

    2015  Volume 231, Page(s) 95–128

    Abstract: The endocannabinoids anandamide and 2-arachidonoylglycerol are metabolised by both hydrolytic enzymes (primarily fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL)) and oxygenating enzymes (e.g. cyclooxygenase-2, COX-2). In the present ... ...

    Abstract The endocannabinoids anandamide and 2-arachidonoylglycerol are metabolised by both hydrolytic enzymes (primarily fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL)) and oxygenating enzymes (e.g. cyclooxygenase-2, COX-2). In the present article, the in vivo data for compounds inhibiting endocannabinoid metabolism have been reviewed, focussing on inflammation and pain. Potential reasons for the failure of an FAAH inhibitor in a clinical trial in patients with osteoarthritic pain are discussed. It is concluded that there is a continued potential for compounds inhibiting endocannabinoid metabolism in terms of drug development, but that it is wise not to be unrealistic in terms of expectations of success.
    MeSH term(s) Amidohydrolases/antagonists & inhibitors ; Amidohydrolases/metabolism ; Analgesics/pharmacology ; Animals ; Anti-Inflammatory Agents/pharmacology ; Cyclooxygenase 2 Inhibitors/pharmacology ; Drug Discovery ; Endocannabinoids/antagonists & inhibitors ; Endocannabinoids/metabolism ; Enzyme Inhibitors/pharmacology ; Fatty Acid-Binding Proteins/antagonists & inhibitors ; Fatty Acid-Binding Proteins/metabolism ; Humans ; Hydrolysis ; Molecular Targeted Therapy ; Monoacylglycerol Lipases/antagonists & inhibitors ; Monoacylglycerol Lipases/metabolism ; Signal Transduction/drug effects
    Chemical Substances Analgesics ; Anti-Inflammatory Agents ; Cyclooxygenase 2 Inhibitors ; Endocannabinoids ; Enzyme Inhibitors ; FABP5 protein, human ; Fatty Acid-Binding Proteins ; Monoacylglycerol Lipases (EC 3.1.1.23) ; Amidohydrolases (EC 3.5.-) ; NAAA protein, human (EC 3.5.1.-) ; fatty-acid amide hydrolase (EC 3.5.1.-)
    Language English
    Publishing date 2015
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 0171-2004
    ISSN 0171-2004
    DOI 10.1007/978-3-319-20825-1_4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs--A practical view.

    Fowler, Christopher J

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

    2015  Volume 25, Issue 6, Page(s) 749–762

    Abstract: The endocannabinoid system, comprising cannabinoid CB1 and CB2 receptors, their endogenous ligands anandamide and 2-arachidonoylglyerol, and their synthetic and metabolic enzymes, are involved in many biological processes in the body, ranging from ... ...

    Abstract The endocannabinoid system, comprising cannabinoid CB1 and CB2 receptors, their endogenous ligands anandamide and 2-arachidonoylglyerol, and their synthetic and metabolic enzymes, are involved in many biological processes in the body, ranging from appetite to bone turnover. Compounds inhibiting the breakdown of anandamide and 2-arachidonoylglycerol increase brain levels of these lipids and thus modulate endocannabinoid signalling. In the present review, the preclinical evidence that these enzymes are good targets for development of novel therapies for anxiety and depression are discussed from a practical, rather than mechanistic, point of view. It is concluded that the preclinical data are promising, albeit tempered by problems of tolerance as well as effects upon learning and memory for irreversible monoacylglycerol lipase inhibitors, and limited by a focus upon male rodents alone. Clinical data so far has been restricted to safety studies with inhibitors of anandamide hydrolysis and a hitherto unpublished study on such a compound in elderly patients with major depressive disorders, but under the dose regimes used, they are well tolerated and show no signs of "cannabis-like" behaviours.
    MeSH term(s) Animals ; Antidepressive Agents/therapeutic use ; Anxiety/drug therapy ; Depression/drug therapy ; Endocannabinoids/antagonists & inhibitors ; Endocannabinoids/metabolism ; Humans
    Chemical Substances Antidepressive Agents ; Endocannabinoids
    Language English
    Publishing date 2015-06
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1082947-7
    ISSN 1873-7862 ; 0924-977X
    ISSN (online) 1873-7862
    ISSN 0924-977X
    DOI 10.1016/j.euroneuro.2015.02.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Has FLAT fallen flat?

    Fowler, Christopher J

    Trends in pharmacological sciences

    2014  Volume 35, Issue 2, Page(s) 51–52

    MeSH term(s) Amidohydrolases/metabolism ; Animals ; Arachidonic Acids/metabolism ; Carrier Proteins/antagonists & inhibitors ; Carrier Proteins/metabolism ; Endocannabinoids/metabolism ; Glycerides/metabolism ; HeLa Cells ; Humans ; Mice ; Polyunsaturated Alkamides/metabolism
    Chemical Substances Arachidonic Acids ; Carrier Proteins ; Endocannabinoids ; Glycerides ; Polyunsaturated Alkamides ; glyceryl 2-arachidonate (8D239QDW64) ; Amidohydrolases (EC 3.5.-) ; fatty-acid amide hydrolase (EC 3.5.1.-) ; anandamide (UR5G69TJKH)
    Language English
    Publishing date 2014-02
    Publishing country England
    Document type Letter
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2013.12.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Transport of endocannabinoids across the plasma membrane and within the cell.

    Fowler, Christopher J

    The FEBS journal

    2013  Volume 280, Issue 9, Page(s) 1895–1904

    Abstract: Endocannabinoids are readily accumulated from the extracellular space by cells. Although their uptake properties have the appearance of a process of facilitated diffusion, it is by no means clear as to whether there is a plasma membrane transporter ... ...

    Abstract Endocannabinoids are readily accumulated from the extracellular space by cells. Although their uptake properties have the appearance of a process of facilitated diffusion, it is by no means clear as to whether there is a plasma membrane transporter dedicated to this task. Intracellular carrier proteins that shuttle the endocannabinoid anandamide from the plasma membrane to its intracellular targets such as the metabolic enzyme, fatty acid amide hydrolase, have been identified. These include proteins with other primary functions, such as fatty-acid-binding proteins and heat shock protein 70, and possibly a fatty acid amide hydrolase-like anandamide transporter protein. Thus, anandamide uptake can be adequately described as a diffusion process across the plasma membrane followed by intracellular carrier-mediated transport to effector molecules, catabolic enzymes and sequestration sites, although it is recognized that different cells are likely to utilize different mechanisms of endocannabinoid transport depending upon the utility of the endocannabinoid for the cell in question.
    MeSH term(s) Amidohydrolases/antagonists & inhibitors ; Amidohydrolases/physiology ; Animals ; Arachidonic Acids/metabolism ; Biological Transport ; Cell Membrane/metabolism ; Cholesterol/physiology ; Endocannabinoids/metabolism ; Enzyme Inhibitors/pharmacology ; Humans ; Membrane Transport Proteins/physiology ; Polyunsaturated Alkamides/metabolism
    Chemical Substances Arachidonic Acids ; Endocannabinoids ; Enzyme Inhibitors ; Membrane Transport Proteins ; Polyunsaturated Alkamides ; Cholesterol (97C5T2UQ7J) ; Amidohydrolases (EC 3.5.-) ; fatty-acid amide hydrolase (EC 3.5.1.-) ; anandamide (UR5G69TJKH)
    Language English
    Publishing date 2013-05
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2173655-8
    ISSN 1742-4658 ; 1742-464X
    ISSN (online) 1742-4658
    ISSN 1742-464X
    DOI 10.1111/febs.12212
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: NSAIDs: eNdocannabinoid stimulating anti-inflammatory drugs?

    Fowler, Christopher J

    Trends in pharmacological sciences

    2012  Volume 33, Issue 9, Page(s) 468–473

    Abstract: Read any pharmacology textbook and the message is clear: nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the activity of cyclooxygenase (COX) and thereby the production of prostaglandins. However, evidence is accumulating that NSAIDs ... ...

    Abstract Read any pharmacology textbook and the message is clear: nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the activity of cyclooxygenase (COX) and thereby the production of prostaglandins. However, evidence is accumulating that NSAIDs involve the endocannabinoid system in their actions, and that such effects may pave the way towards the design of new analgesics that are not plagued with the gastrointestinal and cardiovascular adverse actions that are associated with this class of drugs. In this Opinion article, our current understanding of the involvement of the endocannabinoid system in the actions of NSAIDs is described, and the ways in which this can lead to novel drug development is discussed.
    MeSH term(s) Analgesics/pharmacology ; Animals ; Cannabinoid Receptor Modulators/pharmacology ; Cannabinoid Receptor Modulators/therapeutic use ; Cyclooxygenase Inhibitors/pharmacology ; Drug Discovery ; Endocannabinoids/metabolism ; Humans ; Prostaglandin-Endoperoxide Synthases/metabolism ; Prostaglandins/metabolism
    Chemical Substances Analgesics ; Cannabinoid Receptor Modulators ; Cyclooxygenase Inhibitors ; Endocannabinoids ; Prostaglandins ; Prostaglandin-Endoperoxide Synthases (EC 1.14.99.1)
    Language English
    Publishing date 2012-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2012.05.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Anandamide uptake explained?

    Fowler, Christopher J

    Trends in pharmacological sciences

    2012  Volume 33, Issue 4, Page(s) 181–185

    Abstract: The endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol are removed from the extracellular space by a process of cellular uptake followed by metabolism. Although the enzymes responsible for endocannabinoid metabolism have been well characterised, ...

    Abstract The endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol are removed from the extracellular space by a process of cellular uptake followed by metabolism. Although the enzymes responsible for endocannabinoid metabolism have been well characterised, the processes involved in uptake have been the subject of much controversy. Recent studies, however, have identified intracellular transport proteins (fatty acid binding proteins 5 and 7, heat shock protein 70, albumin, and fatty acid amide hydrolase-like AEA transporter protein) that shuttle AEA from the plasma membrane to its metabolic enzymes. Proteins such as the fatty acid amide hydrolase-like anandamide transporter protein may be useful targets for novel therapeutic strategies aimed at potentiating AEA signalling. In this article I review the current state of the art of endocannabinoid uptake.
    MeSH term(s) Animals ; Arachidonic Acids/metabolism ; Arachidonic Acids/pharmacokinetics ; Cannabinoid Receptor Modulators/metabolism ; Cannabinoid Receptor Modulators/pharmacokinetics ; Carrier Proteins/metabolism ; Cell Membrane/metabolism ; Endocannabinoids ; Humans ; Polyunsaturated Alkamides/metabolism ; Polyunsaturated Alkamides/pharmacokinetics ; Protein Transport
    Chemical Substances Arachidonic Acids ; Cannabinoid Receptor Modulators ; Carrier Proteins ; Endocannabinoids ; Polyunsaturated Alkamides ; anandamide (UR5G69TJKH)
    Language English
    Publishing date 2012-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2012.01.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Exploring the association between cancer and cognitive impairment in the Australian Imaging Biomarkers and Lifestyle (AIBL) study.

    Ma, Liwei / Low, Yi Ling Clare / Zhuo, Yuanhao / Chu, Chenyin / Wang, Yihan / Fowler, Christopher J / Tan, Edwin C K / Masters, Colin L / Jin, Liang / Pan, Yijun

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 4364

    Abstract: An inverse association between cancer and Alzheimer's disease (AD) has been demonstrated; however, the association between cancer and mild cognitive impairment (MCI), and the association between cancer and cognitive decline are yet to be clarified. The ... ...

    Abstract An inverse association between cancer and Alzheimer's disease (AD) has been demonstrated; however, the association between cancer and mild cognitive impairment (MCI), and the association between cancer and cognitive decline are yet to be clarified. The AIBL dataset was used to address these knowledge gaps. The crude and adjusted odds ratios for MCI/AD and cognitive decline were compared between participants with/without cancer (referred to as C+ and C- participants). A 37% reduction in odds for AD was observed in C+ participants compared to C- participants after adjusting for all confounders. The overall risk for MCI and AD in C+ participants was reduced by 27% and 31%, respectively. The odds of cognitive decline from MCI to AD was reduced by 59% in C+ participants after adjusting for all confounders. The risk of cognitive decline from MCI to AD was halved in C+ participants. The estimated mean change in Clinical Dementia Rating-Sum of boxes (CDR-SOB) score per year was 0.23 units/year higher in C- participants than in C+ participants. Overall, an inverse association between cancer and MCI/AD was observed in AIBL, which is in line with previous reports. Importantly, an inverse association between cancer and cognitive decline has also been identified.
    MeSH term(s) Humans ; Neuropsychological Tests ; Australia/epidemiology ; Cognitive Dysfunction/epidemiology ; Cognitive Dysfunction/psychology ; Alzheimer Disease/epidemiology ; Alzheimer Disease/psychology ; Biomarkers ; Life Style ; Neoplasms/complications ; Neoplasms/epidemiology ; Disease Progression
    Chemical Substances Biomarkers
    Language English
    Publishing date 2024-02-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-54875-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Changes in Proportions of Linoleic Acid-derived Oxylipins in Oral Lichen Planus.

    Gouveia-Figueira, Sandra / Danielsson, Karin / Fowler, Christopher J

    Acta dermato-venereologica

    2019  Volume 99, Issue 11, Page(s) 1051–1052

    MeSH term(s) Biopsy ; Case-Control Studies ; Humans ; Lichen Planus, Oral/metabolism ; Linoleic Acid/metabolism ; Oxylipins/metabolism
    Chemical Substances Oxylipins ; Linoleic Acid (9KJL21T0QJ)
    Language English
    Publishing date 2019-07-24
    Publishing country Sweden
    Document type Journal Article
    ZDB-ID 80007-7
    ISSN 1651-2057 ; 0001-5555
    ISSN (online) 1651-2057
    ISSN 0001-5555
    DOI 10.2340/00015555-3281
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top